A Phase I Study of MK-8669 in Patients With Metastatic or Locally Advanced Solid Tumors

Trial Profile

A Phase I Study of MK-8669 in Patients With Metastatic or Locally Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2014

At a glance

  • Drugs Ridaforolimus (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jul 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 07 Jul 2011 Actual initiation date changed from Aug 2008 to Jun 2008 as reported by ClinicalTrials.gov.
    • 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top